AI USE CASE
Adverse Event Prediction from Patient Data
Predict individual adverse drug reaction risk using deep learning on patient genomic and clinical data.
What it is
Deep learning models trained on patient demographics, medical history, and genomic data identify individuals at high risk of adverse drug reactions before or during clinical trials. Early flagging of at-risk patients reduces trial discontinuations, improves participant safety, and can cut adverse event-related delays by 20–40%. Accelerating safety signal detection also shortens overall development timelines and reduces regulatory remediation costs by potentially millions of euros per programme.
Data you need
Longitudinal patient records including demographics, medical history, prior adverse events, lab results, and ideally genomic/pharmacogenomic data at the individual level.
Required systems
- data warehouse
- erp
Why it works
- Establish a federated or centralised, curated data repository with standardised clinical and genomic data schemas before model development begins.
- Engage regulatory affairs and biostatistics teams early to align model validation approach with EMA/FDA expectations.
- Use interpretable model components alongside deep learning to support clinical review and regulatory submission.
- Partner with clinical operations and pharmacovigilance teams to embed predictions into existing safety review workflows.
How this goes wrong
- Insufficient or poorly harmonised genomic and clinical data across trial sites leads to biased or non-generalisable models.
- Regulatory acceptance of AI-derived safety signals is unclear, delaying integration into clinical decision-making.
- Model trained on historical trial populations fails to generalise to new patient demographics or drug classes.
- GDPR and clinical data governance constraints slow data access and model training cycles significantly.
When NOT to do this
Do not pursue this use case if your organisation lacks harmonised, longitudinal patient-level data across multiple trials or cohorts — a shallow dataset will produce a model that appears to validate internally but fails dangerously in production.
Vendors to consider
Sources
This use case is part of a larger Data & AI catalog built from 50+ enterprise transformation programs. Take the free diagnostic to see how it ranks against your specific context.